Overview

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-03-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Phase:
PHASE2
Details
Lead Sponsor:
Bristol-Myers Squibb